Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний
Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний
Насонов Е.Л. Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний. Терапевтический архив. 2019; 91 (8): 98–107. DOI: 10.26442/00403660.2019.08.000406
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Расшифровка иммунопатогенеза, расширение возможностей диагностики и разработка новых методов лечения аутоиммунных заболеваний человека относятся к числу приоритетных направлений медицины XXI в. Особенно широко аутоиммунная патология представлена при иммуновоспалительных ревматических заболеваниях (ИВРЗ), таких как ревматоидный артрит, системная красная волчанка, системная склеродермия, системные васкулиты, связанные с синтезом антинейтрофильных цитоплазматических антител, синдром Шегрена, идиопатические воспалительные миопатии и некоторые другие. Расшифровка механизмов патогенеза ИВРЗ создала предпосылки для совершенствования фармакотерапии, что в перспективе должно привести к кардинальному улучшению прогноза при этих заболеваниях. В обзоре обсуждаются новые подходы к фармакотерапии ИВРЗ, связанные с ингибицией фактора некроза опухоли-α, интерлейкина-6 (ИЛ-6), ИЛ-1β, ИЛ-17, ИЛ-23, перспективы применения ингибиторов Янус-киназы, в зависимости от преобладающих механизмов патогенеза – аутоиммунитета или аутовоспаления.
Ключевые слова: аутоиммунитет, аутовоспаление, моноклональные антитела, ингибиторы Янус-киназы.
Key words: autoimmunity, autoinflammation, monoclonal antibodies, Janus kinase inhibitors.
Ключевые слова: аутоиммунитет, аутовоспаление, моноклональные антитела, ингибиторы Янус-киназы.
________________________________________________
Key words: autoimmunity, autoinflammation, monoclonal antibodies, Janus kinase inhibitors.
Список литературы
1. Насонов Е.Л., Александрова Е.Н., Новиков А.А. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник Российской академии медицинских наук. 2015;70(2):169-82 [Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2015;70(2):169-82 (In Russ.)].
2. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395
3. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280-309. doi: 10.1124/pr.114.009639
4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
5. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419
6. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088
7. Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731
8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;22;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8
9. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-37.
10. Насонов Е.Л. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995-4484-2017-277-294
11. Насонов Е.Л., ред. Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС, 2013 [Nasonov EL, ed. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS, 2013 (In Russ.)].
12. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919
13. Насонов Е.Л. Ревматоидный артрит. В кн.: Насонов Е.Л., ред. Российские клинические рекомендации. M.: ГЭОТАР-Медиа, 2017. C. 17-57 [Nasonov EL. Rheumatoid arthritis. In: Nasonov EL, ed. Rossiiskie klinicheskie rekomendatsii [Russian clinical guidelines]. Moscow: GEOTAR-Media, 2017. P. 17-57 (In Russ.)].
14. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102
15. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
16. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612-27. doi: 10.1038/nrrheuum.2014.123
17. Насонов Е.Л. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433
18. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b
19. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45
20. Stone JH, Tuckwell K, Dimonaco S, Klearman M, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317-28. doi: 10.1056/NEJMoa1613849
21. Сатыбалдыев АМ, Сатыбалдыева МА, Насонов ЕЛ. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и фармакотерапия. 2017;26(1):47-53 [Satybaldyev AM, Satybaldyeva MA, Nasonov EL. Tocilizumab in the treatment of rheumatic polymyalgia and giant cell arteritis. Klinicheskaya Farmakologiya i Farmakoterapiya. 2017;26(1):47-53 (In Russ.)].
22. Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5):536-48 [Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.)]. doi: 10.14412/1995-4484-2017-536-548
23. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593-603. doi: 10.2147/DDDT.S100302
24. June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303-9. doi: 10.1080/14712598.2016.1217988
25. Насонов Е.Л., Станислав М.Л., Раскина Т.А. и др. Эффективность и безопасность сарилумаба в комбинации с метотрексатом у пациентов с активным ревматоидным артритом и неадекватным эффектом монотерапии метотрексатом (результаты исследования III фазы по протоколу MOBILITY). Научно-практическая ревматология. 2019;57(2):142-8 [Nasonov EL, Stanislav ML, Raskina TA, et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):142-8 (In Russ.)]. doi: 10.14412/1995-4484-2019-142-148
26. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Arthritis Rheum. 2017;69(suppl 10).
27. Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071
28. Насонов Е.Л., Лила А.М. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9 [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.)]. doi: 10.14412/1995-4484-2017-590-599
29. Насонов Е.Л. Ингибиция иммунных контрольных точек и аутоиммунитет: ревматологические проблемы. Научно-практическая ревматология. 2018;56(1):5-9 [Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-5-9
30. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12:37-48.
31. Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis. 2018;10(2):29-38. doi: 10.1177/1759720X17752036
32. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084
33. Насонов Е.Л., редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.: ИМА-ПРЕСС, 2012. С. 119-52 [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS, 2012. P. 119-52 (In Russ.)].
34. Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018 Apr 23;9:835.
35. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-904. doi: 10.2147/DDDT.S139248
36. Насонов Е.Л. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-48 [Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.)]. doi: 10.14412/1995-4484-2018-539-548
37. Насонов Е.Л., Решетняк Т.М., Денисов Л.Н., Станислав М.Л., Соловьев С.К. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-9 [Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.)]. doi: 10.14412/1995-4484-2012-1174
38. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73.
39. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10(5):335-6.
40. Асеева Е.А., Соловьев С.К., Меснянкина А.А., Решетняк Т.М., Лопатина Н.Е., Глухова С.И., Насонов Е.Л. Результаты наблюдательного проспективного исследования эффективности и безопасности белимумаба (Бенлисты®) при системной красной волчанке в реальной клинической практике. Научно-практическая ревматология. 2016;54(1):31-7 [Aseeva EA, Soloviev SK, Mesnyankina AA, Reshetnyak TM, Lopatina NE, Glukhova SI, Nasonov EL. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):31-37 (In Russ.)]. doi: 10.14412/1995-4484-2016-31-37
41. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72.
42. Меснянкина А.А., Соловьев С.К., Александрова Е.Н., Алексанкин А.П., Асеева Е.А., Насонов Е.Л. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-8 [Mesnyankina AA, Solovyev SK, Aleksandrova EN, Aleksankin AP, Aseeva EA, Nasonov EL. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-281-288
43. Меснянкина А.А., Соловьев С.К., Асеева Е.А., Насонов Е.Л. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9 [Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-302-309
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61-72.
45. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547-55.
46. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, et al.; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheum. 2018;70(2):266-76.
47. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-8. doi: 10.1038/nrrheum.2011.1
48. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0529-1
49. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
50. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-70. doi: 10.1146/annurev-immunol-051116-052225
51. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20 (Suppl 1):S43-S58.
52. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediat Inflamm. 2015;2015:194864.
53. Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
54. Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166
55. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019 Apr 16;50(4):778-95. doi: 10.1016/j.immuni.2019.03.012
56. Guo H, Callaway JB, Jenny P-Y, Ting J P-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-87. doi: 10.1038/nm.3893
57. Елисеев М.С., Насонов Е.Л. Применение канакинумаба при подагре. Научно-практическая ревматология. 2018;56(Прил. 4):41-8 [Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 4):41-8 (In Russ.)]. doi: 10.14412/1995-4484-2018-41-48
58. Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019 Apr 17;20(8). pii: E1898. doi: 10.3390/ijms20081898
59. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2018 Oct 28. pii: S1521-6616(18)30432-7. doi: 10.1016/j.clim.2018.10.016
60. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017;70(18):2278-89. doi: 10.1016/j.jacc.2017.09.028
61. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
62. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3
63. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated disease. Ann Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-0219444
64. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415-29. doi: 10.1038/nrrheum.2015.53
65. Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 2019;20(5):415-25. doi: 10.1038/s41435-019-0067-y
66. McInnes IB, Porter D, Siebert S. Choosing new targets for rheumatoid arthritis therapeutics: too interesting to Fail? Arthritis Rheum. 2017;69:1131-4.
67. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379-90. doi: 10.1007/s12016-018-8702-3
68. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.000
69. Насонов Е.Л. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86 [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86
70. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579
71. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
72. Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O'Shea JJ. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R
73. Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
74. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18):1987-2001. doi: 10.1007/s40265-017-0835-9
75. Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-30. doi: 10.1080/1744666X.2018
76. Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2018 Apr 3. doi: 10.1093/rheumatology/key070
77. Cinats A, Heck E, Robertson L. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Skin Ther Lett. 2018y;23(3):5-9.
78. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
79. Насонов ЕЛ, Абдулганиева ДИ, Файрушина ИФ. Место тофацитиниба в лечении воспалительных заболеваний кишечника. Терапевтический архив. 2019;91(2):101-8 [Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019;91(2):101-8 (In Russ.)]. doi: 10.26442/00403660.2019.02.000155
80. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2;128(7):2760-2. doi: 10.1172/JCI121526
81. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
82. Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007-14. doi: 10.1111/ijd.14064
83. Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol. 2017;15:86. doi: 10.1186/s12969-017-0212-y
84. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.)]. doi: 10.14412/1995-4484-2019-8-16
85. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
86. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317
87. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23
88. Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018;5(2):567-82. doi: 10.1007/s40744-018-0131-5
89. Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019 May 17:300060519847414. doi: 10.1177/0300060519847414
90. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019;71(1):5-32. doi: 10.1002/art.40726
91. Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340-7.
92. Maksymowych WP, Heijde DV, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390-9. doi: 10.1093/rheumatology/key104
93. Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Jul 13. doi: 10.1007/s10067-018-4199-7
94. Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018;78(7):761-72. doi: 10.1007/s40265-018-0908-4
95. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62. doi: 10.1056/NEJMoa1608345
96. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171-8. doi: 10.1136/annrheumdis-2018-213271
97. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-44. doi: 10.1016/j.jaad.2016.12.005
98. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535-44. doi: 10.1016/j.jaad.2018.04.018
99. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
100. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
101. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
102. Rodero MP, Frémond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.
103. Seo J, Kang J-A, Dong In Suh D, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
104. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
105. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2018 Dec 1. doi: 10.1093/rheumatology/key339
106. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018;19(2). pii: E530. doi: 10.3390/ijms19020530
107. Gaston JSH, Jadon DR. Th17 cell responses in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):777-96. doi: 10.1016/j.berh.2018.07.010
108. Verstockt B, van Assche G, Vermeire S, Ferrante M. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017;17(1):31-47.
109. Papp K, Gordon K, Thaçi D, Morita A, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-21. doi: 10.1056/NEJMoa1806382
110. Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in Autoimmune Rheumatic Diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00
2. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395
3. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280-309. doi: 10.1124/pr.114.009639
4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
5. [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419
6. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088
7. Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731
8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;22;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8
9. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-37.
10. [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995-4484-2017-277-294
11. [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS, 2013 (In Russ.)].
12. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919
13. [Nasonov EL. Rheumatoid arthritis. In: Nasonov EL, ed. Rossiiskie klinicheskie rekomendatsii [Russian clinical guidelines]. Moscow: GEOTAR-Media, 2017. P. 17-57 (In Russ.)].
14. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102
15. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
16. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612-27. doi: 10.1038/nrrheuum.2014.123
17.[Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433
18. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b
19. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45
20. Stone JH, Tuckwell K, Dimonaco S, Klearman M, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317-28. doi: 10.1056/NEJMoa1613849
21. [Satybaldyev AM, Satybaldyeva MA, Nasonov EL. Tocilizumab in the treatment of rheumatic polymyalgia and giant cell arteritis. Klinicheskaya Farmakologiya i Farmakoterapiya. 2017;26(1):47-53 (In Russ.)].
22. [Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.)]. doi: 10.14412/1995-4484-2017-536-548
23. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593-603. doi: 10.2147/DDDT.S100302
24. June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303-9. doi: 10.1080/14712598.2016.1217988
25. [Nasonov EL, Stanislav ML, Raskina TA, et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):142-8 (In Russ.)]. doi: 10.14412/1995-4484-2019-142-148
26. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Arthritis Rheum. 2017;69(suppl 10).
27. Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071
28.[Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.)]. doi: 10.14412/1995-4484-2017-590-599
29. [Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-5-9
30. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12:37-48.
31. Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis. 2018;10(2):29-38. doi: 10.1177/1759720X17752036
32. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084
33. [Anti-B cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS, 2012. P. 119-52 (In Russ.)].
34. Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018 Apr 23;9:835.
35. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-904. doi: 10.2147/DDDT.S139248
36. [Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.)]. doi: 10.14412/1995-4484-2018-539-548
37. [Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.)]. doi: 10.14412/1995-4484-2012-1174
38. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73.
39. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10(5):335-6.
40. [Aseeva EA, Soloviev SK, Mesnyankina AA, Reshetnyak TM, Lopatina NE, Glukhova SI, Nasonov EL. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):31-37 (In Russ.)]. doi: 10.14412/1995-4484-2016-31-37
41. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72.
42. [Mesnyankina AA, Solovyev SK, Aleksandrova EN, Aleksankin AP, Aseeva EA, Nasonov EL. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-281-288
43. [Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-302-309
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61-72.
45. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547-55.
46. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, et al.; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheum. 2018;70(2):266-76.
47. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-8. doi: 10.1038/nrrheum.2011.1
48. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0529-1
49. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
50. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-70. doi: 10.1146/annurev-immunol-051116-052225
51. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20 (Suppl 1):S43-S58.
52. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediat Inflamm. 2015;2015:194864.
53. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
54. Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166
55. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019 Apr 16;50(4):778-95. doi: 10.1016/j.immuni.2019.03.012
56. Guo H, Callaway JB, Jenny P-Y, Ting J P-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-87. doi: 10.1038/nm.3893
57. [Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 4):41-8 (In Russ.)]. doi: 10.14412/1995-4484-2018-41-48
58. Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019 Apr 17;20(8). pii: E1898. doi: 10.3390/ijms20081898
59. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2018 Oct 28. pii: S1521-6616(18)30432-7. doi: 10.1016/j.clim.2018.10.016
60. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017;70(18):2278-89. doi: 10.1016/j.jacc.2017.09.028
61. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
62. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3
63. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated disease. Ann Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-0219444
64. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415-29. doi: 10.1038/nrrheum.2015.53
65. Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 2019;20(5):415-25. doi: 10.1038/s41435-019-0067-y
66. McInnes IB, Porter D, Siebert S. Choosing new targets for rheumatoid arthritis therapeutics: too interesting to Fail? Arthritis Rheum. 2017;69:1131-4.
67. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379-90. doi: 10.1007/s12016-018-8702-3
68. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.000
69. [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86
70. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579
71. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
72. Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O'Shea JJ. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R
73. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
74. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18):1987-2001. doi: 10.1007/s40265-017-0835-9
75. Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-30. doi: 10.1080/1744666X.2018
76. Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2018 Apr 3. doi: 10.1093/rheumatology/key070
77. Cinats A, Heck E, Robertson L. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Skin Ther Lett. 2018y;23(3):5-9.
78. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
79. [Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019;91(2):101-8 (In Russ.)]. doi: 10.26442/00403660.2019.02.000155
80. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2;128(7):2760-2. doi: 10.1172/JCI121526
81. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
82. Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007-14. doi: 10.1111/ijd.14064
83. Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol. 2017;15:86. doi: 10.1186/s12969-017-0212-y
84.[Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.)]. doi: 10.14412/1995-4484-2019-8-16
85. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
86. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317
87. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23
88. Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018;5(2):567-82. doi: 10.1007/s40744-018-0131-5
89. Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019 May 17:300060519847414. doi: 10.1177/0300060519847414
90. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019;71(1):5-32. doi: 10.1002/art.40726
91. Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340-7.
92. Maksymowych WP, Heijde DV, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390-9. doi: 10.1093/rheumatology/key104
93. Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Jul 13. doi: 10.1007/s10067-018-4199-7
94. Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018;78(7):761-72. doi: 10.1007/s40265-018-0908-4
95. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62. doi: 10.1056/NEJMoa1608345
96. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171-8. doi: 10.1136/annrheumdis-2018-213271
97. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-44. doi: 10.1016/j.jaad.2016.12.005
98. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535-44. doi: 10.1016/j.jaad.2018.04.018
99. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
100. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
101. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
102. Rodero MP, Frémond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.
103. Seo J, Kang J-A, Dong In Suh D, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
104. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
105. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2018 Dec 1. doi: 10.1093/rheumatology/key339
106. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018;19(2). pii: E530. doi: 10.3390/ijms19020530
107. Gaston JSH, Jadon DR. Th17 cell responses in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):777-96. doi: 10.1016/j.berh.2018.07.010
108. Verstockt B, van Assche G, Vermeire S, Ferrante M. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017;17(1):31-47.
109. Papp K, Gordon K, Thaçi D, Morita A, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-21. doi: 10.1056/NEJMoa1806382
110. Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in Autoimmune Rheumatic Diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00
2. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395
3. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280-309. doi: 10.1124/pr.114.009639
4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
5. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419
6. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088
7. Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731
8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;22;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8
9. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-37.
10. Насонов Е.Л. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995-4484-2017-277-294
11. Насонов Е.Л., ред. Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС, 2013 [Nasonov EL, ed. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS, 2013 (In Russ.)].
12. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919
13. Насонов Е.Л. Ревматоидный артрит. В кн.: Насонов Е.Л., ред. Российские клинические рекомендации. M.: ГЭОТАР-Медиа, 2017. C. 17-57 [Nasonov EL. Rheumatoid arthritis. In: Nasonov EL, ed. Rossiiskie klinicheskie rekomendatsii [Russian clinical guidelines]. Moscow: GEOTAR-Media, 2017. P. 17-57 (In Russ.)].
14. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102
15. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
16. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612-27. doi: 10.1038/nrrheuum.2014.123
17. Насонов Е.Л. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433
18. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b
19. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45
20. Stone JH, Tuckwell K, Dimonaco S, Klearman M, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317-28. doi: 10.1056/NEJMoa1613849
21. Сатыбалдыев АМ, Сатыбалдыева МА, Насонов ЕЛ. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и фармакотерапия. 2017;26(1):47-53 [Satybaldyev AM, Satybaldyeva MA, Nasonov EL. Tocilizumab in the treatment of rheumatic polymyalgia and giant cell arteritis. Klinicheskaya Farmakologiya i Farmakoterapiya. 2017;26(1):47-53 (In Russ.)].
22. Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5):536-48 [Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.)]. doi: 10.14412/1995-4484-2017-536-548
23. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593-603. doi: 10.2147/DDDT.S100302
24. June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303-9. doi: 10.1080/14712598.2016.1217988
25. Насонов Е.Л., Станислав М.Л., Раскина Т.А. и др. Эффективность и безопасность сарилумаба в комбинации с метотрексатом у пациентов с активным ревматоидным артритом и неадекватным эффектом монотерапии метотрексатом (результаты исследования III фазы по протоколу MOBILITY). Научно-практическая ревматология. 2019;57(2):142-8 [Nasonov EL, Stanislav ML, Raskina TA, et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):142-8 (In Russ.)]. doi: 10.14412/1995-4484-2019-142-148
26. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Arthritis Rheum. 2017;69(suppl 10).
27. Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071
28. Насонов Е.Л., Лила А.М. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9 [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.)]. doi: 10.14412/1995-4484-2017-590-599
29. Насонов Е.Л. Ингибиция иммунных контрольных точек и аутоиммунитет: ревматологические проблемы. Научно-практическая ревматология. 2018;56(1):5-9 [Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-5-9
30. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12:37-48.
31. Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis. 2018;10(2):29-38. doi: 10.1177/1759720X17752036
32. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084
33. Насонов Е.Л., редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.: ИМА-ПРЕСС, 2012. С. 119-52 [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS, 2012. P. 119-52 (In Russ.)].
34. Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018 Apr 23;9:835.
35. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-904. doi: 10.2147/DDDT.S139248
36. Насонов Е.Л. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-48 [Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.)]. doi: 10.14412/1995-4484-2018-539-548
37. Насонов Е.Л., Решетняк Т.М., Денисов Л.Н., Станислав М.Л., Соловьев С.К. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-9 [Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.)]. doi: 10.14412/1995-4484-2012-1174
38. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73.
39. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10(5):335-6.
40. Асеева Е.А., Соловьев С.К., Меснянкина А.А., Решетняк Т.М., Лопатина Н.Е., Глухова С.И., Насонов Е.Л. Результаты наблюдательного проспективного исследования эффективности и безопасности белимумаба (Бенлисты®) при системной красной волчанке в реальной клинической практике. Научно-практическая ревматология. 2016;54(1):31-7 [Aseeva EA, Soloviev SK, Mesnyankina AA, Reshetnyak TM, Lopatina NE, Glukhova SI, Nasonov EL. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):31-37 (In Russ.)]. doi: 10.14412/1995-4484-2016-31-37
41. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72.
42. Меснянкина А.А., Соловьев С.К., Александрова Е.Н., Алексанкин А.П., Асеева Е.А., Насонов Е.Л. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-8 [Mesnyankina AA, Solovyev SK, Aleksandrova EN, Aleksankin AP, Aseeva EA, Nasonov EL. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-281-288
43. Меснянкина А.А., Соловьев С.К., Асеева Е.А., Насонов Е.Л. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9 [Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-302-309
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61-72.
45. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547-55.
46. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, et al.; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheum. 2018;70(2):266-76.
47. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-8. doi: 10.1038/nrrheum.2011.1
48. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0529-1
49. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
50. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-70. doi: 10.1146/annurev-immunol-051116-052225
51. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20 (Suppl 1):S43-S58.
52. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediat Inflamm. 2015;2015:194864.
53. Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
54. Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166
55. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019 Apr 16;50(4):778-95. doi: 10.1016/j.immuni.2019.03.012
56. Guo H, Callaway JB, Jenny P-Y, Ting J P-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-87. doi: 10.1038/nm.3893
57. Елисеев М.С., Насонов Е.Л. Применение канакинумаба при подагре. Научно-практическая ревматология. 2018;56(Прил. 4):41-8 [Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 4):41-8 (In Russ.)]. doi: 10.14412/1995-4484-2018-41-48
58. Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019 Apr 17;20(8). pii: E1898. doi: 10.3390/ijms20081898
59. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2018 Oct 28. pii: S1521-6616(18)30432-7. doi: 10.1016/j.clim.2018.10.016
60. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017;70(18):2278-89. doi: 10.1016/j.jacc.2017.09.028
61. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
62. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3
63. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated disease. Ann Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-0219444
64. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415-29. doi: 10.1038/nrrheum.2015.53
65. Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 2019;20(5):415-25. doi: 10.1038/s41435-019-0067-y
66. McInnes IB, Porter D, Siebert S. Choosing new targets for rheumatoid arthritis therapeutics: too interesting to Fail? Arthritis Rheum. 2017;69:1131-4.
67. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379-90. doi: 10.1007/s12016-018-8702-3
68. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.000
69. Насонов Е.Л. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86 [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86
70. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579
71. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
72. Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O'Shea JJ. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R
73. Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
74. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18):1987-2001. doi: 10.1007/s40265-017-0835-9
75. Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-30. doi: 10.1080/1744666X.2018
76. Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2018 Apr 3. doi: 10.1093/rheumatology/key070
77. Cinats A, Heck E, Robertson L. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Skin Ther Lett. 2018y;23(3):5-9.
78. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
79. Насонов ЕЛ, Абдулганиева ДИ, Файрушина ИФ. Место тофацитиниба в лечении воспалительных заболеваний кишечника. Терапевтический архив. 2019;91(2):101-8 [Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019;91(2):101-8 (In Russ.)]. doi: 10.26442/00403660.2019.02.000155
80. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2;128(7):2760-2. doi: 10.1172/JCI121526
81. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
82. Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007-14. doi: 10.1111/ijd.14064
83. Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol. 2017;15:86. doi: 10.1186/s12969-017-0212-y
84. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.)]. doi: 10.14412/1995-4484-2019-8-16
85. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
86. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317
87. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23
88. Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018;5(2):567-82. doi: 10.1007/s40744-018-0131-5
89. Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019 May 17:300060519847414. doi: 10.1177/0300060519847414
90. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019;71(1):5-32. doi: 10.1002/art.40726
91. Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340-7.
92. Maksymowych WP, Heijde DV, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390-9. doi: 10.1093/rheumatology/key104
93. Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Jul 13. doi: 10.1007/s10067-018-4199-7
94. Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018;78(7):761-72. doi: 10.1007/s40265-018-0908-4
95. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62. doi: 10.1056/NEJMoa1608345
96. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171-8. doi: 10.1136/annrheumdis-2018-213271
97. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-44. doi: 10.1016/j.jaad.2016.12.005
98. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535-44. doi: 10.1016/j.jaad.2018.04.018
99. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
100. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
101. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
102. Rodero MP, Frémond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.
103. Seo J, Kang J-A, Dong In Suh D, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
104. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
105. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2018 Dec 1. doi: 10.1093/rheumatology/key339
106. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018;19(2). pii: E530. doi: 10.3390/ijms19020530
107. Gaston JSH, Jadon DR. Th17 cell responses in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):777-96. doi: 10.1016/j.berh.2018.07.010
108. Verstockt B, van Assche G, Vermeire S, Ferrante M. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017;17(1):31-47.
109. Papp K, Gordon K, Thaçi D, Morita A, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-21. doi: 10.1056/NEJMoa1806382
110. Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in Autoimmune Rheumatic Diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00
________________________________________________
2. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395
3. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280-309. doi: 10.1124/pr.114.009639
4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
5. [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419
6. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088
7. Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731
8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;22;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8
9. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328-37.
10. [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995-4484-2017-277-294
11. [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS, 2013 (In Russ.)].
12. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919
13. [Nasonov EL. Rheumatoid arthritis. In: Nasonov EL, ed. Rossiiskie klinicheskie rekomendatsii [Russian clinical guidelines]. Moscow: GEOTAR-Media, 2017. P. 17-57 (In Russ.)].
14. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102
15. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.
16. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612-27. doi: 10.1038/nrrheuum.2014.123
17.[Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433
18. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b
19. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45
20. Stone JH, Tuckwell K, Dimonaco S, Klearman M, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317-28. doi: 10.1056/NEJMoa1613849
21. [Satybaldyev AM, Satybaldyeva MA, Nasonov EL. Tocilizumab in the treatment of rheumatic polymyalgia and giant cell arteritis. Klinicheskaya Farmakologiya i Farmakoterapiya. 2017;26(1):47-53 (In Russ.)].
22. [Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.)]. doi: 10.14412/1995-4484-2017-536-548
23. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593-603. doi: 10.2147/DDDT.S100302
24. June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303-9. doi: 10.1080/14712598.2016.1217988
25. [Nasonov EL, Stanislav ML, Raskina TA, et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):142-8 (In Russ.)]. doi: 10.14412/1995-4484-2019-142-148
26. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Arthritis Rheum. 2017;69(suppl 10).
27. Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071
28.[Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.)]. doi: 10.14412/1995-4484-2017-590-599
29. [Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-5-9
30. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12:37-48.
31. Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis. 2018;10(2):29-38. doi: 10.1177/1759720X17752036
32. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084
33. [Anti-B cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS, 2012. P. 119-52 (In Russ.)].
34. Hofmann K, Clauder AK, Manz RA. Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front Immunol. 2018 Apr 23;9:835.
35. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 2017;11:2891-904. doi: 10.2147/DDDT.S139248
36. [Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.)]. doi: 10.14412/1995-4484-2018-539-548
37. [Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.)]. doi: 10.14412/1995-4484-2012-1174
38. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73.
39. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10(5):335-6.
40. [Aseeva EA, Soloviev SK, Mesnyankina AA, Reshetnyak TM, Lopatina NE, Glukhova SI, Nasonov EL. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):31-37 (In Russ.)]. doi: 10.14412/1995-4484-2016-31-37
41. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72.
42. [Mesnyankina AA, Solovyev SK, Aleksandrova EN, Aleksankin AP, Aseeva EA, Nasonov EL. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-281-288
43. [Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.)]. doi: 10.14412/1995-4484-2018-302-309
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61-72.
45. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547-55.
46. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, et al.; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheum. 2018;70(2):266-76.
47. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-8. doi: 10.1038/nrrheum.2011.1
48. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0529-1
49. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
50. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-70. doi: 10.1146/annurev-immunol-051116-052225
51. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20 (Suppl 1):S43-S58.
52. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediat Inflamm. 2015;2015:194864.
53. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77
54. Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166
55. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019 Apr 16;50(4):778-95. doi: 10.1016/j.immuni.2019.03.012
56. Guo H, Callaway JB, Jenny P-Y, Ting J P-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-87. doi: 10.1038/nm.3893
57. [Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 4):41-8 (In Russ.)]. doi: 10.14412/1995-4484-2018-41-48
58. Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019 Apr 17;20(8). pii: E1898. doi: 10.3390/ijms20081898
59. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2018 Oct 28. pii: S1521-6616(18)30432-7. doi: 10.1016/j.clim.2018.10.016
60. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017;70(18):2278-89. doi: 10.1016/j.jacc.2017.09.028
61. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
62. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3
63. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated disease. Ann Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-0219444
64. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415-29. doi: 10.1038/nrrheum.2015.53
65. Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 2019;20(5):415-25. doi: 10.1038/s41435-019-0067-y
66. McInnes IB, Porter D, Siebert S. Choosing new targets for rheumatoid arthritis therapeutics: too interesting to Fail? Arthritis Rheum. 2017;69:1131-4.
67. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379-90. doi: 10.1007/s12016-018-8702-3
68. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.000
69. [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86
70. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579
71. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
72. Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O'Shea JJ. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R
73. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi: 10.14412/1995-4484-2014-209-221
74. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18):1987-2001. doi: 10.1007/s40265-017-0835-9
75. Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-30. doi: 10.1080/1744666X.2018
76. Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2018 Apr 3. doi: 10.1093/rheumatology/key070
77. Cinats A, Heck E, Robertson L. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Skin Ther Lett. 2018y;23(3):5-9.
78. Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003
79. [Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019;91(2):101-8 (In Russ.)]. doi: 10.26442/00403660.2019.02.000155
80. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2;128(7):2760-2. doi: 10.1172/JCI121526
81. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
82. Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007-14. doi: 10.1111/ijd.14064
83. Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol. 2017;15:86. doi: 10.1186/s12969-017-0212-y
84.[Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.)]. doi: 10.14412/1995-4484-2019-8-16
85. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
86. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317
87. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23
88. Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018;5(2):567-82. doi: 10.1007/s40744-018-0131-5
89. Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019 May 17:300060519847414. doi: 10.1177/0300060519847414
90. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019;71(1):5-32. doi: 10.1002/art.40726
91. Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340-7.
92. Maksymowych WP, Heijde DV, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390-9. doi: 10.1093/rheumatology/key104
93. Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Jul 13. doi: 10.1007/s10067-018-4199-7
94. Al-Salama ZT, Scott LJ. Baricitinib: A Review in Rheumatoid Arthritis. Drugs. 2018;78(7):761-72. doi: 10.1007/s40265-018-0908-4
95. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62. doi: 10.1056/NEJMoa1608345
96. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171-8. doi: 10.1136/annrheumdis-2018-213271
97. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-44. doi: 10.1016/j.jaad.2016.12.005
98. Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535-44. doi: 10.1016/j.jaad.2018.04.018
99. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
100. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
101. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
102. Rodero MP, Frémond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.
103. Seo J, Kang J-A, Dong In Suh D, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
104. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
105. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2018 Dec 1. doi: 10.1093/rheumatology/key339
106. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018;19(2). pii: E530. doi: 10.3390/ijms19020530
107. Gaston JSH, Jadon DR. Th17 cell responses in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):777-96. doi: 10.1016/j.berh.2018.07.010
108. Verstockt B, van Assche G, Vermeire S, Ferrante M. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017;17(1):31-47.
109. Papp K, Gordon K, Thaçi D, Morita A, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-21. doi: 10.1056/NEJMoa1806382
110. Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in Autoimmune Rheumatic Diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00
Авторы
Е.Л. Насонов 1,2
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
________________________________________________
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.